Frontiers in cellular and infection microbiology · 2025
Multi-drug resistant Clostridioides difficile isolate ST81 is prominent in hematological patients in a teaching hospital in China.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Qi, Bian YaoQian, Wei XinJun, Xiao Shuzhen, Xu Zizhen, Li Hui, Li Qingtian, Wei Beiwen, Huang Jiewen, Song Zhen, Zhao Yanan
Аннотация
INTRODUCTION: Clostridioides difficile Infection (CDI) is more prevalent in people with hematologic diseases. However, epidemiological characteristics are poorly understood.
METHODS: From July 2016 to November 2021, we studied the epidemiology of CDI in patients with hematological diseases at a tertiary teaching hospital in Shanghai, China.
RESULTS: In hematological patients, the prevalence of CDI was 21.6%, with 89.8% hospital-acquired infections. C. difficile ST81, which is a multidrug-resistant strain carrying only the toxin B, is the most common strain (38.1%), followed by ST3 (16.7%) and ST2 (9.5%). Clindamycin and moxifloxacin resistance rates of all C. difficile species were 64.3% and 31%, respectively, and no isolate was resistant to vancomycin, linezolid, metronidazole, teicoplanin, or daptomycin.
DISCUSSION: This study provides a comprehensive characterization of CDI in hematological patients, highlighting the urgent need for enhanced surveillance and preventive strategies against this emerging nosocomial threat.
METHODS: From July 2016 to November 2021, we studied the epidemiology of CDI in patients with hematological diseases at a tertiary teaching hospital in Shanghai, China.
RESULTS: In hematological patients, the prevalence of CDI was 21.6%, with 89.8% hospital-acquired infections. C. difficile ST81, which is a multidrug-resistant strain carrying only the toxin B, is the most common strain (38.1%), followed by ST3 (16.7%) and ST2 (9.5%). Clindamycin and moxifloxacin resistance rates of all C. difficile species were 64.3% and 31%, respectively, and no isolate was resistant to vancomycin, linezolid, metronidazole, teicoplanin, or daptomycin.
DISCUSSION: This study provides a comprehensive characterization of CDI in hematological patients, highlighting the urgent need for enhanced surveillance and preventive strategies against this emerging nosocomial threat.